Groundbreaking Discovery: Manchester Scientists Uncover 'Unique' Early Breast Cancer Detection Method!

Scientists at the University of Manchester and The Christie are pioneering a novel approach to breast cancer detection, investigating whether testing breast milk could provide a 'unique' and earlier diagnosis compared to conventional methods. This groundbreaking research focuses on identifying circulating tumour DNA shed by cancer cells within breast milk, a bio-fluid that has been remarkably under-researched until now.

The urgent need for improved detection methods is underscored by the challenges associated with pregnancy-related breast cancer. Dr. Niki Flaum, a consultant oncologist at The Christie and leader of the study, highlights that diagnosis during and after pregnancy is often delayed due to the unreliability of traditional breast imaging techniques in these periods. This can lead to diagnoses at later stages when the cancer has already spread, resulting in significantly worse survival outcomes for affected women compared to those of similar age who have not recently given birth.

While breastfeeding is known to reduce the long-term risk of breast cancer, women face a heightened risk during pregnancy and the postpartum period. Pregnancy-related breast cancer affects approximately one in 3,000 pregnancies, with the risk escalating to as high as one in 50 for individuals at higher genetic risk, such as those carrying a faulty BRCA gene.

Dr. Florent Mouliere's research team has made a significant breakthrough by identifying tiny, unique fragments of genetic material shed by cells in donated breast milk samples. Understanding the structure of this DNA is a crucial step forward, potentially paving the way for a reliable screening tool. The goal is to develop an approach that can detect cancer-related DNA in breast milk, which could then be tested for its efficacy as a screening tool for women with existing breast cancer or those at high risk.

The Christie is actively funding this research and has begun recruiting 40 women who are currently producing breast milk. This initial cohort includes 25 women from the general population risk group and 15 from a high-risk category with a family history of breast cancer. The broader ambition is to establish a Manchester Breast Biofluid Biobank, aiming to collect over 200 samples for extensive future research. These samples will be meticulously analyzed at the National Biomarker Centre at The Christie by the University of Manchester team.

Hannah Brennan, a 31-year-old registered midwife and PhD student at the University of Manchester, is one of the mothers contributing to this vital research. Motivated by her grandmother's death from breast cancer at an early age and her desire to help other women, Hannah views her participation as a straightforward process involving a blood sample, breast milk donation, and a few questions. She encourages other breastfeeding mothers to take part, emphasizing the potential for her small contribution to make a significant difference for future mothers.

Louise Hadley, chief executive of The Christie Charity, reiterated the organization's commitment to this important research. She emphasized its potential to improve early detection in high-risk women, including BRCA carriers, enable specific screening for pregnancy-related breast cancer, and help predict the risk of postpartum breast cancer. Furthermore, it could offer reassurance to high-risk women who wish to breastfeed but are often advised to stop early to resume MRI screening. The Christie Charity is dedicated to providing £30 million in funding by 2030 to support game-changing discoveries in Manchester, with immense gratitude for donor support.